Top Page
Semler Scientific
(NASDAQ:SMLR)
Semler Scientific (SMLR) vs. SPDR S&P 500 ETF (SPY)
Semler Scientific Business Overview & Revenue Model
Semler Scientific Earnings Call Summary
Semler Scientific Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 42.98M | 56.29M | 68.18M | 56.69M | 53.03M | 38.60M |
| Gross Profit | 39.04M | 51.53M | 61.20M | 52.43M | 46.91M | 35.25M |
| EBITDA | -22.89M | 21.51M | 23.28M | 17.79M | 19.45M | 15.96M |
| Net Income | 37.05M | 40.90M | 20.58M | 14.32M | 17.22M | 14.01M |
Balance Sheet | ||||||
| Total Assets | 522.60M | 239.83M | 78.06M | 62.69M | 50.67M | 34.64M |
| Cash, Cash Equivalents and Short-Term Investments | 13.48M | 14.92M | 57.20M | 43.09M | 37.32M | 22.08M |
| Total Debt | 96.28M | 70.00K | 160.00K | 245.00K | 325.00K | 332.00K |
| Total Liabilities | 139.19M | 9.08M | 6.27M | 7.02M | 5.13M | 4.85M |
| Stockholders Equity | 383.41M | 230.75M | 71.80M | 55.68M | 45.55M | 29.79M |
Cash Flow | ||||||
| Free Cash Flow | -117.31M | 24.36M | 20.50M | 15.30M | 15.23M | 14.36M |
| Operating Cash Flow | 12.46M | 24.41M | 21.33M | 17.46M | 16.06M | 15.42M |
| Investing Cash Flow | -366.41M | -189.98M | 18.40M | -26.84M | -825.00K | -1.31M |
| Financing Cash Flow | 360.10M | 117.19M | -5.41M | -4.94M | 13.00K | 230.00K |
Semler Scientific Technical Analysis
Semler Scientific Risk Analysis
Semler Scientific Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $540.77M | 11.37 | 16.04% | ― | -30.39% | 46.15% | |
52 Neutral | $489.70M | -3.64 | -25.57% | ― | -1.36% | -479.49% | |
52 Neutral | $590.74M | ― | -3.36% | ― | -2.18% | -30.96% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $444.41M | ― | -59.78% | ― | ― | ― | |
47 Neutral | $426.57M | ― | -12.67% | ― | 19.90% | -57.90% | |
43 Neutral | $383.03M | ― | -15.36% | ― | -0.02% | -1196.44% |
Semler Scientific Corporate Events
Semler Scientific is currently conducting the QuantaFlo HD Clinical Validation Study, aimed at assessing cardiovascular function through innovative methods. The study’s primary objective is to validate the correlation between echocardiography-measured GLS values and blood flow responses during forced expiration, using the QuantaFlo HD device. This research holds significant potential for advancing cardiovascular diagnostics.
Semler Scientific has launched a dashboard on its website to disclose information about its Bitcoin holdings, fulfilling its disclosure obligations under Regulation FD. This dashboard will provide key performance indicators and market data, encouraging investors to regularly review the updates for material information.
The most recent analyst rating on (SMLR) stock is a Hold with a $32.00 price target. To see the full list of analyst forecasts on Semler Scientific stock, see the SMLR Stock Forecast page.
On April 15, 2025, Semler Scientific, Inc. entered into a Master Loan Agreement with Coinbase Credit Inc., allowing it to borrow cash or digital assets, collateralized by Bitcoin. On September 25, 2025, Semler Sci borrowed $20 million from Coinbase Credit at a 10% interest rate, using Bitcoin as collateral, to settle a previous obligation with the U.S. Department of Justice.
The most recent analyst rating on (SMLR) stock is a Hold with a $32.00 price target. To see the full list of analyst forecasts on Semler Scientific stock, see the SMLR Stock Forecast page.
On September 22, 2025, Semler Scientific, Inc. entered into a Merger Agreement with Strive, Inc., a Nevada corporation. Under the agreement, a subsidiary of Strive will merge with Semler Sci, making it a wholly owned subsidiary of Strive. This merger, approved by both companies’ boards, aims to qualify as a reorganization under U.S. federal income tax laws. The transaction involves converting Semler Sci’s common stock into Strive’s Class A common stock at a specified exchange ratio. The merger is subject to customary closing conditions, including shareholder approvals and regulatory consents. The merger agreement includes provisions for termination fees and conditions under which the agreement can be terminated by either party.
The most recent analyst rating on (SMLR) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on Semler Scientific stock, see the SMLR Stock Forecast page.
On September 22, 2025, Semler Scientific and Strive, Inc. announced a merger agreement where Strive will acquire Semler in an all-stock transaction. This merger, approved by both companies’ boards, is expected to enhance Strive’s position as a leading Bitcoin treasury company and expand Semler’s diagnostics business into preventative care. The transaction includes a significant premium for Semler’s stockholders and aims to drive shareholder value through innovative Bitcoin strategies and expanded healthcare services.
The most recent analyst rating on (SMLR) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on Semler Scientific stock, see the SMLR Stock Forecast page.
Semler Scientific has reported a decline in the usage of its QuantaFlo device due to changes in Medicare Advantage and Part D rates, with a significant customer planning to reduce its usage from October 1, 2025. This is expected to result in a substantial drop in fourth-quarter revenues for 2025. Additionally, the company faces a lawsuit filed on August 29, 2025, by a stockholder alleging violations of securities laws, which Semler Scientific intends to contest.
The most recent analyst rating on (SMLR) stock is a Hold with a $36.00 price target. To see the full list of analyst forecasts on Semler Scientific stock, see the SMLR Stock Forecast page.
On September 5, 2025, Semler Scientific held its annual meeting of stockholders where several key proposals were voted upon. Stockholders elected William H.C. Chang as a Class I Director and approved the executive compensation on a non-binding advisory basis. They also approved an amendment to increase the authorized shares of common stock from 50 million to 210 million. However, the proposal to authorize the issuance of 42 million shares of ‘blank-check’ preferred stock was not approved. Additionally, the selection of BDO USA, P.C. as the independent registered public accounting firm for 2025 was ratified.
The most recent analyst rating on (SMLR) stock is a Hold with a $36.00 price target. To see the full list of analyst forecasts on Semler Scientific stock, see the SMLR Stock Forecast page.
Semler Scientific faces a significant business risk due to its potential reliance on third-party intellectual property for the development and commercialization of its vascular testing products. If a third party holds essential patent rights, Semler may need to secure licenses to use this technology. However, these licenses may not be available or could be offered on terms that are not commercially viable, posing a substantial threat to the company’s business operations and financial health.
Semler Scientific’s recent earnings call painted a mixed picture with significant achievements in Bitcoin acquisitions and unrealized gains contributing to a robust net income. However, these positive developments were tempered by declines in healthcare revenue and operating losses, alongside legal expenses. The company’s dual focus on Bitcoin and healthcare presents both opportunities and challenges.